NEW YORK (GenomeWeb) – Cancer Genetics today announced that is has signed in-network provider agreements with Blue Cross Blue Shield (BCBS) of North Carolina, BCBS Nebraska, and WellMark.
The deals open up the firm's molecular diagnostic testing to a combined customer base of 6.7 million people, Cancer Genetics said in a statement.
"Developing relationships with leading regional and national payer organizations is central to our strategy," Randy Goodman, director of reimbursement and clinical revenue cycle management at Cancer Genetics, said in a statement. "CGI's new agreements with these three providers represent a significant milestone in our larger corporate strategy, which is geared toward increasing health plan reimbursement for our genomic testing platforms and offering our services to a wider patient community."
WellMark comprises the BCBS networks in Iowa and North Dakota. The provider agreements are the latest in a series of agreements with payors for Cancer Genetics, including recent deals to provide testing services to BCBS of Illinois, Harvard Pilgrim Healthcare, and America's Choice Provider Network.